Flot.bio x Philip Hemme

Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49

Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting.The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first approved allogeneic T‑cell therapy. We also explore his new position as an operating partner at Jeito and how we need to work harder to find Europe’s hidden biotech gems.-----------------------------------------------------------------------Get expert legal advisory support for growing your biotech from Osborne Clarke at https://bit.ly/oc-flotbio----------------------------------------------------------------------⭐️ ABOUT THE SPEAKERWith many years of experience in big pharma, Pascal had top-level positions at Novartis Oncology. He later served as CEO, and most recently Chairman, of Atara Biotherapeutics. Alongside his Jeito role, he sits on the boards of companies including Ipsen, Medincell, Catalym, Xylocor and CDR-Life.🔗 LINKS MENTIONEDJeito’s website: https://www.jeito.life/en/home/Stefano Portolano, Azafaros | Rare Diseases, Small Molecules Revival | E40: https://www.youtube.com/watch?v=gdaPW7xg_qkOtello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/pascal-touchon-jeito/ 💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:40] The rise of Kymriah and Ebvallo[00:05:40] CAR-T: crazy innovations and valuations[00:20:35] Solid tumor challenges[00:23:18] Cell therapy manufacturing and in vivo CAR-T[00:31:38] Catching the innovation wave at Jeito Capital[00:39:29] VC models and European biotech gems[00:52:51] Biotech without borders[01:05:49] France’s rising pharma stars [01:08:30] Quick-fire questions

Werner Lanthaler 🇦🇹 | Biopharma AI, CDMO, Antibody Optimization | E48

Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and hard to solve, Werner told Philip in Vienna.We revisit Werner in Vienna after he left Evotec and went on a sabbatical in 2024. We talk about his new missions as FairJourney CEO and founder of WLAN Holdings, and discuss the global CDMO scene and Europe’s competitivity in biotech.And while it's still early days yet, we find out AI will transform the way we work in biopharma going forward, with new generations of companies shaping their business models around it.⭐️ ABOUT THE SPEAKERWerner is the new CEO of FairJourney Biologics and invests with his holding. He served as CEO of Evotec from 2009 to 2024, expanding the company’s revenues and workforce. Prior to this, he was the CFO of Intercell in Austria for nine years.🔗 LINKS MENTIONEDWLAN Holding’s website - [](https://tiltbio.com/) https://wlanholding.com/Werner Lanthaler, Evotec | Leading AI in Biotech | E02 -- https://flot.bio/episode/werner-lanthaler-evotec-ai-in-biotech/Antoine Papiernik, Sofinnova | Billion Investing with Balance | E01 — https://flot.bio/episode/antoine-papiernik-sofinnova-ebillion-biotech-investing-with-balance/Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39 — https://flot.bio/episode/alex-zhavoronkov-insilico-medicine-ai-drug-development-longevity/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/werner-lanthaler-biopharma-ai/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:09] Werner Lanthaler: from Evotec to new roles[00:06:01] WLAN Holding and the benefits of a sabbatical[00:10:58] Inside the Evotec departure[00:13:13] Joining FairJourney Biologics[00:20:33] The job market in Europe[00:23:49] CDMO competition and China[00:28:07] Letting European biotech compete globally[00:34:50] How AI has overpromised in biopharma[00:48:09] Quick-fire questions

Thomas Lingelbach, Valneva | Vaccines, Lyme Disease | E47

Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry.⭐️ ABOUT THE SPEAKERA veteran in the development of more than ten vaccines, Thomas has spent over 30 years in the vaccine space and has served in senior roles at the companies Intercell, Novartis and Chiron. Thomas was with Intercell since 2006 and was the CEO when the company merged with Vivalis to form Valneva in 2013.🔗 LINKS MENTIONEDValneva’s website - https://valneva.com/Valneva’s Half Year 2025 Financial Results - https://valneva.com/press-release/valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates/Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/thomas-lingelbach-valneva-vaccines/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ Timestamps[00:00:00] Intro[00:03:09] Duck cell vaccines[00:04:55] The grandpa of French and Austrian biotech[00:15:09] Products for chikungunya, Japanese encephalitis and cholera[00:22:04] Valneva and Pfizer’s Lyme disease vaccine[00:29:46] Navigating US anti-vaccine turbulence[00:33:33] The stormy biotech investment market[00:36:32] Thomas Lingelbach talks financials[00:39:46] Quick-fire questions

Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46

When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team.⭐️ ABOUT THE SPEAKERMarc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinCor Pharma and Corvidia Therapeutics). He also served as CEO of Ipsen from 2010 to 2016, and has worked at the likes of Amgen and Eli Lilly.🔗 LINKS MENTIONEDAbivax’s website - https://www.abivax.com/Phase 3 results - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week$747.5 million public offering - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-7475-million-public-offeringMarc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09 - https://flot.bio/episode/marc-de-garidel-abivax-exit/Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34 - https://flot.bio/episode/chris-martin-verona-pharma-copd/Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/Nanobiotix episode - https://www.youtube.com/watch?v=3Krhyy6a-nw&pp=0gcJCQMKAYcqIYzvFabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43 - https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/📜 TRANSCRIPT Read the full transcript here:💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS0:44: Abivax’s crazy Ph3 data and stock price jump4:06: Surging investor demand on NASDAQ and Euronext8:58: Future directions11:02: Executing a Phase 3 home run17:20: Marc de Garidel's leadership style21:58: Abivax: origins34:51: France's billion-dollar biotechs44:11: Quick-fire questions

Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45

As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to partner with giants like Johnson & Johnson, and how Laurent’s leadership style has evolved over his long tenure.⭐️ ABOUT THE SPEAKERLaurent Lévy co-founded Nanobiotics in 2003 and has served as CEO ever since. Before this, he worked in a variety of roles with companies including Altran Technologies, Valbiotis and Sanofi.He has a doctorate in nanomaterials-focused physical chemistry from the Pierre and Marie Curie University in Paris.🔗 LINKS MENTIONEDNanobiotix website -- https://nanobiotix.com/Nanobiotix's $71 million deal with Healthcare Royalty -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-strategic-royalty-monetization-agreementNanobiotix's first phase 1 data -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-first-data-phase-1-study-evaluating-jnj📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:11] Soaring stocks with clinical results[00:04:08] Nanobiotix's history[00:07:39] Nanoparticles and radiotherapy[00:13:42] Developing NBTXR3[00:25:02] Universal cancer radiotherapy enhancers[00:28:28] Few competitors[00:33:37] Biotech in France, Europe and the US[00:37:19] Laurent Lévy’s leadership style[00:42:16] Quick-fire questions